Search

Your search keyword '"Pan-cancer"' showing total 3,867 results

Search Constraints

Start Over You searched for: Descriptor "Pan-cancer" Remove constraint Descriptor: "Pan-cancer"
3,867 results on '"Pan-cancer"'

Search Results

1. Somatic CpG hypermutation is associated with mismatch repair deficiency in cancer.

2. Gene clusters-based pathway enrichment analysis identifies four pan-cancer subtypes with distinct molecular and clinical features.

3. Comprehensive Analysis and Experimental Validation of the Parkinson's Disease Lysosomal Gene ACP2 and Pan-cancer.

4. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.

5. Identification of ETV5 as a prognostic marker related to epigenetic modification in pan-cancer and facilitates tumor progression in hepatocellular carcinoma.

6. Single-cell multiomics reveals simvastatin inhibits pan-cancer epithelial-mesenchymal transition via the MEK/ERK pathway in XBP1+ mast cells.

7. A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers.

8. Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis.

9. GLN2 as a key biomarker and therapeutic target: evidence from a comprehensive pan-cancer study using molecular, functional, and bioinformatic analyses.

10. Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis.

11. Pan-cancer landscape of DCTPP1 and preliminary exploration of DCTPP1 in renal clear cell carcinoma.

12. Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer.

13. EDNRA regulates the tumour immune environment and predicts the efficacy and prognosis of cancer immunotherapy.

14. Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer.

15. Integrated pan-cancer analysis and experimental verification of the roles of ZBED3 in kidney renal clear cell carcinoma.

16. Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy.

17. The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer.

18. Translocase of Outer Mitochondrial Membrane 40, as a Promising Biomarker for the Diagnosis of Polycystic Ovary Syndrome and Pan-Cancer.

19. Pan-cancer analysis of BRK1 as a potential immunotherapeutic target.

20. A pan-cancer analysis of the role of WDFY2 in human tumors.

21. Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response.

22. mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC.

23. Developmental-status-aware transcriptional decomposition establishes a cell state panorama of human cancers.

24. Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses.

25. Discovery of Jaspamycin from marine-derived natural product based on MTA3 to inhibit hepatocellular carcinoma progression.

26. Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance.

27. Pan-cancer analysis and experimental validation of FPR3 as a prognostic and immune infiltration-related biomarker for glioma.

28. The pan‐cancer landscape presented ITGA7 as a prognostic determinant, tumor suppressor, and oncogene in multiple tumor types.

29. Metabolic Reprogramming Induced by Aging Modifies the Tumor Microenvironment.

30. Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.

31. PER3 promoter hypermethylation correlates to the progression of pan-cancer.

32. The prognostic and immune significance of Rab11A in pan‐cancer and its function and mechanism underlying estrogen receptor targeting in breast cancer.

33. The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer.

34. SPECC1 as a pan-cancer biomarker: unraveling its role in drug sensitivity and resistance mechanisms.

35. EBNA1BP2 identified as potential prognostic biomarker for multiple tumor types in pan-cancer analysis.

36. STARD7 could be an immunological and prognostic biomarker: from pan-cancer analysis to hepatocellular carcinoma validation.

37. Neutrophil chemotaxis score and chemotaxis-related genes have the potential for clinical application to prognosticate the survival of patients with tumours.

38. Pan-cancer analysis of the prognostic and immunological roles of SHP-1/ptpn6.

39. The relationship between polymorphism of IGF2BP2 gene rs4402960 and risk of pan-cancer: a meta-analysis and a bioinformatics analysis.

40. Novel Oncogenic Value of C10orf90 in Colon Cancer Identified as a Clinical Diagnostic and Prognostic Marker.

41. A Pan-Cancer Analysis of Ferroptosis-Related Gene Arachidonic Acid 15-Lipoxygenase-1 (ALOX15): Its Prognostic and Immunotherapeutic Values.

42. Interplay of RNA m 6 A Modification-Related Geneset in Pan-Cancer.

43. The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.

44. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment.

45. Analysis of the Potential Link Between Dermatomyositis and Cancer

46. Elucidating the role of MICAL1 in pan-cancer using integrated bioinformatics and experimental approaches

47. Identification of ETV5 as a prognostic marker related to epigenetic modification in pan-cancer and facilitates tumor progression in hepatocellular carcinoma

48. Single-cell multiomics reveals simvastatin inhibits pan-cancer epithelial-mesenchymal transition via the MEK/ERK pathway in XBP1+ mast cells

49. Identification of gasdermin B function in the progression of renal clear cell carcinoma by a pan-cancer analysis

50. Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis

Catalog

Books, media, physical & digital resources